Pfizer: Accupril (Quinapril HCl) tablets 10mg, 20mg, 40 mg — FDA announcement Apr 22, 2022

Reported terminated

A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.

Source date Apr 22, 2022. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.

What the record says

Product
Accupril (Quinapril HCl) tablets 10mg, 20mg, 40 mg
Reason
Due to N-Nitroso-Quinapril Content
Classification
Not supplied
Recalling firm
Pfizer
Quantity
Not supplied
Agency-reported status
Terminated in FDA listing
Source record identifier
477f4de31f266499

Open the official record

Lot and product identifiers

Label fieldDetails supplied by the agency
Lot, code or applicabilityThe NDC, Lot Number, Expiration Date, and Configuration details for these products are indicated in the tables below and photos of the products can be found at the end of this press release. The product lots were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from December 2019 to April 2022.; NDC | Lot Number | Expiration Date | Strength | Configuration/ Count; 0071-0530-23 | DR9639 | 2023 MAR 31 | 10 mg | 1 x 90 count bottle; 0071-0532-23 | DX8682 | 2023 MAR 31 | 20 mg | 1 x 90 count bottle; DG1188 | 2022 MAY 31 | 20 mg | 1 x 90 count bottle; 0071-0535-23 | DX6031 | 2023 MAR 31 | 40 mg | 1 x 90 count bottle; CK6260 | 2022 MAY 31 | 40 mg | 1 x 90 count bottle; Contact Center | Contact Information | Area of Support; Pfizer Medical Information | 800-438-1985, option 3 (Mon.- Fri. 8 am-9 pm ET) www.pfizermedinfo.com | For medical questions regarding the product; Pfizer Drug Safety | 800-438-1985, option 1 (24 hours a day; 7 days a | To report adverse events and product

Match all identifying details in the current notice. A brand name alone is not enough.

Product tables from the announcement

These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.

FDA company announcement, table 1
NDC Lot Number Expiration Date Strength Configuration/ Count
0071-0530-23 DR9639 2023 MAR 31 10 mg 1 x 90 count bottle
0071-0532-23 DX8682 2023 MAR 31 20 mg 1 x 90 count bottle
DG1188 2022 MAY 31 20 mg 1 x 90 count bottle
0071-0535-23 DX6031 2023 MAR 31 40 mg 1 x 90 count bottle
CK6260 2022 MAY 31 40 mg 1 x 90 count bottle
FDA company announcement, table 2
Contact Center Contact Information Area of Support
Pfizer Medical Information 800-438-1985, option 3 (Mon.- Fri. 8 am-9 pm ET) www.pfizermedinfo.com For medical questions regarding the product
Pfizer Drug Safety 800-438-1985, option 1 (24 hours a day; 7 days a To report adverse events and product

Announcement retrieved Oct 1, 2026. Official announcement.

Distribution

The NDC, Lot Number, Expiration Date, and Configuration details for these products are indicated in the tables below and photos of the products can be found at the end of this press release. The product lots were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from December 2019 to April 2022.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

Dates in the source

Fda listing date
Apr 22, 2022
Company announcement date
Apr 22, 2022

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

Related records